Sab Biotherapeutics Inc. Class WSABSWPreferred / convertible
13F holders, Q4 2025 (December 31)7holders −3
1new positions
4sold out
$0.03avg. 13F price*
At the end of Q4 2025, 7 institutions reported holding Sab Biotherapeutics Inc. Class W (SABSW) in their 13F filings, down 3 from Q3 2025. 1 opened new positions and 4 sold out. The largest holders were Morgan Stanley ($5K), Clear Street Group Inc. ($2K) and GTS Securities LLC ($1K).
- Company
- Sab Biotherapeutics Inc. Class W
- CUSIP
- 78397T111
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $1K |
| Exits | 4 | $14K |
All 13F filers, Q3 2025 → Q4 2025: 41,101 shares bought and 595,054 shares sold, net −553,953 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 7 holders
| Morgan Stanley | — | No change | 146,439 | $5K |
| Clear Street Group Inc. | — | Reduce -0.3% | 78,833 | $2K |
| GTS Securities LLC | — | New | 41,101 | $1K |
| UBS Group AG | — | Reduce -73.6% | 6,186 | $192 |
| Wolverine Asset Management LLC | — | No change | 1,811 | $57 |
| NewEdge Advisors, LLC | — | No change | 1,072 | $33 |
| Bank of America Corp. | — | Reduce -50.0% | 100 | $3 |
"% of holder's portfolio" is SABSW's weight in each manager's 13F, not the share of Sab Biotherapeutics Inc. Class W the manager owns.